盐酸氨溴索静脉滴注联合布地奈德雾化吸入治疗小儿支气管肺炎的临床效果  

Clinical effect of intravenous infusion of ambroxol hydrochloride combined with nebulized budesonide inhalation in the treatment of pediatric bronchopneumonia

作　　者：陈燕红 CHEN Yan-hong(Department of Pediatrics,Jinjiang City Hospital(Shanghai Sixth People's Hospital Fujian Hospital),Quanzhou 362200,China)

机构地区：[1]晋江市医院(上海市第六人民医院福建医院)儿科,362200

出　　处：《中国现代药物应用》2025年第2期87-90,共4页Chinese Journal of Modern Drug Application

摘　　要：目的 分析盐酸氨溴索静脉滴注联合布地奈德雾化吸入治疗对小儿支气管肺炎的效果。方法 选择100例支气管肺炎患儿为研究对象,随机分为观察组(采用盐酸氨溴索静脉滴注联合布地奈德雾化吸入治疗,50例)和对照组(采用盐酸氨溴索静脉滴注治疗,50例)。比较两组患儿治疗效果,治疗前后炎症因子水平,治疗前后咳嗽评分,临床症状改善时间及住院时间,不良反应发生率。结果 观察组患儿总有效率98.00%(49/50)显著高于对照组的86.00%(43/50)(P<0.05)。治疗前两组炎症因子肿瘤坏死因子α(TNF-α)、超敏C反应蛋白(hs-CRP)以及降钙素原(PCT)水平比较差异无统计学意义(P>0.05);治疗后两组患儿炎症因子TNF-α、hs-CRP以及PCT水平均明显低于治疗前,且观察组炎症因子TNF-α(80.23±16.56)ng/L、hs-CRP(2.56±0.51)mg/L、PCT(0.89±0.26)μg/L明显低于对照组的(95.11±15.81)ng/L、(4.65±1.01)mg/L、(1.56±0.35)μg/L(P<0.05)。治疗前两组患儿的日间及夜间咳嗽评分比较差异无统计学意义(P>0.05);治疗后,两组患儿的日间及夜间咳嗽评分均低于治疗前,且观察组患儿的日间咳嗽评分(1.32±0.51)分及夜间咳嗽评分(1.30±0.06)分明显低于对照组的(1.65±0.50)、(1.50±0.08)分(P<0.05)。观察组患儿的体温恢复时间、住院时间、气促消失时间、肺部湿啰音消失时间分别为(2.98±0.65)、(7.56±1.53)、(4.56±0.65)、(5.32±1.23)d均短于对照组的(3.26±0.54)、(9.65±1.81)、(6.15±0.88)、(7.56±1.63)d(P<0.05)。观察组出现恶心、呕吐各1例,不良反应发生率4.00%(2/50);对照组出现恶心2例、呕吐1例,不良反应发生率6.00%(3/50);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论 盐酸氨溴索静脉滴注联合布地奈德雾化吸入治疗小儿支气管肺炎效果显著,症状改善迅速,可明显缓解患儿机体炎症状态,且治疗安全性较高。Objective To analyze the effect of intravenous infusion of ambroxol hydrochloride combined with nebulized budesonide inhalation in the treatment of pediatric bronchopneumonia.Methods A total of100 pediatric patients with bronchopneumonia were selected as the research subjects,and were randomly divided into observation group(intravenous infusion of ambroxol hydrochloride combined with nebulized budesonide inhalation,50 cases) and control group(intravenous infusion of ambroxol hydrochloride,50 cases).Comparison was made on treatment effect,levels of inflammatory factors before and after treatment,cough symptom score before and after treatment,improvement time of clinical symptoms,hospitalization time and incidence of adverse reactions between the two groups.Results The total effective rate of 98.00%(49/50) in the observation group was significantly higher than 86.00%(43/50) in the control group(P<0.05).Before treatment,there was no significant difference in the levels of tumor necrosis factor-α(TNF-α),hypersensitive C-reactive protein(hs-CRP) and procalcitonin(PCT) between the two groups(P>0.05).After treatment,the levels of inflammatory factors TNF-α,hs-CRP and PCT in both groups were significantly lower than those before treatment;the observation group had TNF-α of(80.23±16.56) ng/L,hs-CRP of(2.56±0.51) mg/L and PCT of(0.89±0.26) μg/L,which were significantly lower than(95.11±15.81) ng/L,(4.65±1.01) mg/L and(1.56±0.35) μg/L in the control group(P<0.05).Before treatment,there was no significant difference in daytime and nighttime cough scores between the two groups(P>0.05).After treatment,the daytime and nighttime cough scores in both groups were lower than those before treatment;the daytime and nighttime cough scores were(1.32±0.51) and(1.30±0.06) points in the observation group,which were significantly lower than(1.65±0.50) and(1.50±0.08) points in the control group(P<0.05).The recovery time of body temperature,hospitalization time,disappearance time of shortness of breath and disappearance time

关 键 词：盐酸氨溴索 布地奈德 小儿支气管肺炎 静脉滴注 雾化吸入 安全性 

分 类 号：R725.6[医药卫生—儿科]